Renal Data from the Arab World
|
|
- Piers Lamb
- 6 years ago
- Views:
Transcription
1 Saudi J Kidney Dis Transpl 2011;22(4): Saudi Center for Organ Transplantation Saudi Journal of Kidney Diseases and Transplantation Renal Data from the Arab World Why does Kidney Allograft Fail? A Long-term Single-center Experience Sameer Alarrayed, Amgad El-Agroudy, Ahmed Al-Arrayed, Sumaya Ghareeb, Eman Farid, Taysir Garadah, Sadiq Abdulla Nephrology and Kidney Transplantation Department, Salmaniya Medical Complex, MOH, College of Medicine, Arabian Gulf University, Manama, Kingdom of Bahrain ABSTRACT. We studied the characteristics and the predictors of survival in Bahraini renal transplant recipients with an allograft that functioned for more than 10 years. Seventy-eight patients underwent renal transplantation between 1982 and Among them, 56 patients maintained functioning allografts for more than 10 years (range years). Characteristics of the surviving patients, data on graft survival, and determinants of outcome were obtained by reviewing all medical records. The mean age at time of renal transplantation was 33.6 ± 15.3 years. The source of the graft in 42 (75%) recipients was from living related donors with a mean age of 31.4 ± 7.7 years, and it was the first graft in 48 recipients. The primary immunosuppression regimen consisted of cyclosporine (CsA) and prednisolone. Azathioprine (AZA) was given to 52 (92.9%) recipients, while four patients received steroids and AZA only. Induction therapy was administered to 30 patients in the CsA group. Acute rejection episodes occurred in eight (14.3%) patients, of whom two experienced two episodes. During the last follow-up in January 2010, the mean serum creatinine was ± 46.5 µmol/l. A history of cancer was noted in one patient, whereas hypertension was encountered in 54% and diabetes mellitus in 20.5%. We compared the graft functioning group with the graft failure group and found that the independent determinants of long-term graft survival included time of late acute rejection episodes and histopathologic findings of chronic allograft damage, posttransplant hypertension and serum creatinine at one year. We conclude that renal transplantation even in its earliest years and despite the associated numerous complications has provided a ten-year or more of near-normal life to patients with end-stage renal disease. Correspondence to: Dr. Sameer Alarrayed, Consultant, Head of Nephrology and Kidney Transplantation Department, Salmaniya Medical Complex, Ministry of Health, Manama, Kingdom of Bahrain salarrayed@yahoo.com Introduction Kidney transplantation restoring continuous renal functions represents the most physiological replacement therapy for chronic end-stage renal disease (ESRD). Recipients of successful transplants enjoy a higher quality of life, which for obvious reasons is directly linked to the continued normal graft function. 1
2 Long-term renal allograft survival in Bahrain 819 During the last two decades, a significant progress has been achieved in the graft and patient survival rates after renal transplantation. 2 Although numerous reports on 1- and 5-year survival of kidney grafts and their recipients have been published, data on 10-year survival or more are scarce. The factors influencing longterm survival of the graft are still being debated and the only one fully accepted is kidney origin, i.e. those from living donors survive longer than those from the deceased. 2-6 Predictors of long-term graft survival in patients who receive live-donor grafts are of special interest because they depend less on donor factors in comparison with the patients receiving grafts from deceased donors. 7 The aim of this study is to determine the nature of complications and study the characteristics and define the predictors of survival observed in live-donor renal transplant recipients in our center with an allograft that functioned for more than ten years. This is the first report of long-term follow-up of renal transplantation recipients from our country. Patients and Methods We reviewed 82 consecutive live-donor renal transplantations performed at our center (Al- Moayyed Nephrology and Transplant Center, Salmaniya Medical Complex, Manama, Bahrain) between March 1982 and December Four recipients were excluded because of graft failure that occurred during the first year posttransplantation and or due to technical reasons. We included in this study 56 (71.8%) renal transplant recipients who maintained functioning grafts for more than ten years (range years). Forty-two (75%) patients received allografts from related donors. The patients data included clinical parameters, laboratory tests, and various medical and surgical complications, and they were documented chronologically on their flow sheets. The graft function was monitored by serum creatinine and calculated creatinine clearance (ccrcl) using the Cockroft-Gault formula. Hypertension was defined as systolic blood pressure (SBP) >140 mmhg and/or diastolic blood pressure (DBP) >90 mmhg and graded according to the number of anti-hypertensive medications. Diabetes mellitus was defined as fasting blood glucose of >120 mg/dl. Any bacterial, viral, or fungal infection was diagnosed by specific investigations and cultures as appropriate. Other complications including cardiovascular morbidities and history of malignancy were also recorded. There were four patients transplanted before 1983 and received daily oral combined therapy of prednisolone mg and azathioprine (AZA) 3 mg/kg. From 1983 onward, there were 52 patients who received renal allograft and were maintained on oral triple immunosuppressive regimen comprising daily prednisolone (5-10 mg/day), cyclosporine (CsA) at a dose of 10 mg/kg, adjusted to keep CsA whole-blood trough level between 200 and 250 ng/ml in the first two months and then between 100 and 150 ng/ml thereafter, and either AZA 1 mg/kg (45 patients) or mycophenolate mofetil (MMF) (seven patients). Induction therapy was used in 30 patients in the form of intravenous baziliximab 20 mg on days zero and four post-transplantation. All acute rejection episodes were documented by biopsy and treated by administering intravenous methylprednisolone 500 mg daily for five days. Steroid-resistant episodes were treated with antibody therapy: antithymocyte globulin (ATG), or orthoclone (OKT3). In order to characterize parameters associated with poor graft survival, we compared two groups of patients using univariate and multivariate analyses for different variables that may affect the graft survival: patients who had functioning grafts for more than ten years (graft surviving group) and those who had failed grafts before this period (graft non-surviving group). Statistical Analysis For univariate analysis, t -test was used in numeric data, which were homogenously distributed, while nonparametric Mann-Whitney test was used for non-homogenously distributed numeric data. A multivariate analysis of graft survival was performed using Cox proportional ha-
3 820 Alarrayed S, El-Agroudy A, Al-Arrayed A, et al Table 1. Characteristics of the study subgroups. Graft surviving group Failed graft group P (n = 56) (n = 22) Recipient age at transplant, years (Mean ± SD) 3.6 ± ± Recipient sex (M/F) 38/18 14/8 0.7 Donor age, years (Mean ± SD) 31.4 ± ± Donor sex (M/F) 40/16 12/ Donor source (related/unrelated) 42/14 17/5 0.6 Causes of end-stage kidney diseases (%) 0.06 Interstitial nephritis 6 (10.7) 2 (9.1) Glomerulonephritis 5 (8.9 3 (13.7) Others 16 (28.6) 8 (12.3) Inapplicable 29 (51.8) 9 (40.9) HLA mismatches 3 (%) 25 (44.6) 9 (40.9) 0.2 Pre-emptive transplant (%) 10 (17.9) 2 (13.6) 0.2 Retransplantation (%) 8 (14.3) 2 (1.8) 0.5 Pre-transplant hypertension (%) 23 (41.1) 13 (59.1) 0.02 Primary immunosuppression (%) 0.5 AZA-prednisolone 4 (7.1) 1 (4.6) CsA-AZA-prednisolone 43 (76.8) 18 (81.8) CsA-MMF-prednisolone 8 (16.1) 3 (13.6) zards regression models to adjust for the potentially confounding variables that could influence outcomes. The SPSS statistics package (SPSS V17.0, SPSS Inc., Chicago, IL, USA) was used for these analyses. P value <0.05 was considered statistically significant. Results The demographic and clinical characteristics of the long-term allograft survivors showed that most of the recipients were males and in the middle age (33.6 ± 15.3 years) at the time of transplantation. Most of the donors were also males of middle age. The patients were followed up for a mean period of 171 ± 48.1 months (range months) (Table 1). The immunological variables demonstrated that more than 75% received grafts from related donors. There were 14 recipients of renal allograft from unrelated living donors, who were transplanted outside our center. Most of the recipients had less than three human leukocyte antigen (HLA) mismatches (41 cases). Determination of the data on panel reactive antibody (PRA) levels was possible in 13 patients and all were less than 10%. The mean of the serum creatinine levels at the last follow-up was 118 ± 46.5 µmol/l (range µmol/l), with a mean proteinuria level of 0.47 g/day. There were only three patients with proteinuria equal to or just slightly greater than 2 g/day. The complications in our study patients are shown in Table 2. Acute rejection episodes occurred in eight patients (14.2%); most of them were within the first year post-transplantation. The first acute rejection episode occurred at a median time of 15 days post-transplantation. All these episodes responded promptly to high-dose steroid therapy except in two (3.6%) patients whose graft function did not recover completely and progressed to biopsy-proven chronic rejection. Chronic graft dysfunction (CAD) was histologically diagnosed in the allograft biopsies of 12 patients presenting clinically with this complication. There were four biopsies that showed moderate chronic interstitial fibrosis and tubular atrophy (25-50%) as described by Banff classification 8 and the others showed mild findings. Staining for c4d was possible in only four cases and all were negative. The mean of the SBP and DBP measurements was 145 ± 18 and 85 ± 8 mmhg, respectively. Also, 40.1% of the patients received one anti-hypertensive drug and 59.9% received two drugs. Hypertension was
4 Long-term renal allograft survival in Bahrain 821 Table 2. Post-transplant clinical events in the study subgroups. Graft surviving Failed graft P group group (n = 56) (n = 22) ATN (%) - 1 (4.5) 0.3 Acute rejection episodes Frequency (1/ 2) 6/2 5/ Severity (mild, grade I/grade II, III) 7/3 7/ Resistant to steroids (%) 2 (3.6) 2 (9.1) 0.05 Date of first episode, days (Mean ± SD) 18.0 ± ± Date of last episode, days (Mean ± SD) 956 ± ± Chronic allograft nephropathy (%) 12 (21.4) 17 (77.2) Graft function Serum creatinine at 3 months, µmol/l (Mean ± SD) 79.1 ± ± Serum creatinine at 12 months, µmol/l (Mean ± SD) 98.1 ± ± Proteinuria (>2 g/l) at 12 months (%) 3 (5.4) 4 (18.2) 0.04 Cyclosporine doses at 3 months, mg/day (Mean ± SD) 196 ± ± Post-transplant complications (%) Hypertension 17 (54.2) 85 (75.2) Diabetes mellitus 6 (10.7) 3 (13.6) 0.06 Infection 11 (19.6) 5 (4.5) 0.3 Malignancy 3 (5.4) 1 (9.7) 0.08 Hepatic dysfunction 5 (8.9) 6 (13.2) 0.5 Cardiovascular 7 (12.5) 4 (18.8) 0.06 was detected more frequently in patients with serum creatinine levels >161 ± 26.1 µmol/l and associated with post-transplant proteinuria. Coronary artery disease was documented in seven (12.5%) patients, and three (5.4%) had history of arrhythmia. Hypercholesterolemia was present in 43.1% patients; 21 patients received one of the cholesterol reducing agents. Post-transplant diabetes mellitus (PTDM) was diagnosed in six (10.7%) patients and its control was maintained with insulin therapy in two, while diet regimen and oral hypoglycemic agents were prescribed in the rest. All PTDM patients had family history of diabetes mellitus and five of them were obese [body mass index (BMI) > 30%]. Post-transplant infection developed at least once in 11 (19.6%) patients. The majority of these were urinary tract infections (eight patients), upper respiratory tract infections (six patients) and herpes zoster (three patients). Serious infections that required hospitalization included pneumococcal pneumonia, which was treated with intravenous broad-spectrum antibiotics in four patients, and cytomegalovirus (CMV) infection in two, which was treated with intravenous gancyclovir therapy. Development of malignancy occurred in three patients (5.4%). One female patient developed thyroid cancer after ten years and was treated by reduction of immunosuppression and by radiotherapy, with a favorable response. The other two male patients developed prostate cancer after 12 and 13 years post-transplant. They responded well to gradual reduction of their immunosuppression and removal of the prostate gland. Assessment of quality of life showed that 70% of the study patients had normal activity without any difficulties. More than 50% of the patients returned back to their previous jobs. We compared patients who had functioning grafts for more than ten years with those who had lost them before. The significant predictors for long-term graft survival included pre-transplant hypertension, CsA dose at one year, severity and frequency of acute rejection episodes, time of late acute rejection episodes, presence of CAD and serum creatinine 12 months after transplantation, significant post-transplant proteinuria (more than 2 g/24 hours), and post-trans-
5 822 Alarrayed S, El-Agroudy A, Al-Arrayed A, et al The half-life for cadaver and living related allografts had improved to 13.8 and 21.6 years, respectively. 9 Our results show that graft survival rate is 71.8% after more than ten years of follow-up. El-Agroudy and his group 4 found that 62 renal transplant recipients out of 144 patients (43%) had a functioning graft for more than 15 years (range years). Tojimbara et al 7 found that graft survival in kidney transplant recipients from deceased donor was 44% and 23% after 20 and 15 years, respectively, while Kyllonen and his group 10 reported that 107 patients out of 824 kidney transplants (15%) had functioning grafts longer than 20 years. The incidence of various long-term complications found in our study is similar to those reported previously in patients with graft survival equal to or greater than ten years. Hypertension was the most common complication that occurred in 54.2% of patients. The overall prevalence of hypertension among kidney transplant recipients ranges, in most series, between 70% and 80% In our series, we observed that post-transplant hypertension was more pre- Table 3. Characteristics of long-term renal allograft survivors according to the primary immunosuppression. AZA-Pred. CsA-AZA- CsA-MMF- P group Pred. group Pred. group (n = 4) (n = 43) (n = 9) Acute rejection episodes Frequency (1/ 2) 1/- 5/2 1/ Severity (mild, grade I/grade II, III) 1/1 4/2 1/1 0.3 Resistant to steroids Date of first episode, days (Mean ± SD) 14.8 ± ± ± Chronic allograft nephropathy (%) 1 (25) 9 (20.9) 2 (22.2) 0.1 Post-transplant hypertension (%) 1 (25) 22 (46.5) 2 (22.2) 0.04 Post-transplant infections (%) 1 (25) 8 (18.6) 2 (22.2) 0.3 Post-transplant diabetes mellitus (%) - 4 (9.3) 1 (11.1) 0.06 Post-transplant cardiovascular morbidity (%) - 8 (18.6) 2 (22.2) 0.03 Serum creatinine, µmol/l (Mean ± SD) At 3 months 69.1 ± ± ± At 12 months 75.3 ± ± ± At last follow-up 102 ± ± ± ccrcl at last follow-up (ml/min) (Mean ± SD) 88 ± ± ± Clinical grading (last follow-up visit) (%) 0.06 Excellent (Cr. 150 µmol/l) 3 (75) 27 (62.8) 7 (77.8) Good (Cr µmol/l) 1 (25) 13 (30.2) 1 (11.1) Moderate (Cr. 250 µmol/l) - 3 (7) 1 (11.1) plant hypertension. The multivariate analysis shortlisted these predictors to the time of late acute rejection episodes [relative risk (RR) 0.29, P < ], serum creatinine at one year (RR 0.18, P < 0.001), presence of severe CAD (RR 0.23, P < ), and post-transplant hypertension (RR 0.16, P < 0.009). The characteristics of long-term renal allograft survivors (n = 56) according to the primary immunosuppression, AZA and prednisolone treated patients (n = 4), CsA, prednisolone and AZA treated patients (n = 43) and CsA, prednisolone and MMF treated patients (n = 9), are shown in Table 3. In all the groups, the difference in serum creatinine at 3 and 12 months after transplantation was statistically significant, but not at the last follow-up (P = 0.09). The numbers and the severity of acute rejection episodes together with response to treatment were not significantly different. There was no significant difference between all the groups with regard to post-transplant CAD, diabetes mellitus and infection. However, there were more patients complicated with hypertension and cardiovascular events in both CsA treated groups (P = 0.04 and 0.03, respectively). Discussion
6 Long-term renal allograft survival in Bahrain 823 valent in the CsA-treated patients, in parallel with rising serum creatinine and in the presence of proteinuria. Long-term allograft and patient survival may be negatively influenced by posttransplant hypertension. In a large study of 29,751 renal transplant recipients, the presence of hypertension was significantly associated with allograft loss. 15 The RR of graft failure with the use of anti-hypertensive medications was 1.42 for live donor grafts and 1.58 for deceased donor grafts, indicating an approximately 40-50% excess risk of graft failure for patients who required these medications. Our data demonstrate that post-transplant hypertension had a deleterious effect on renal allograft survival. Several reports described the role of pre-transplantation hypertension in the development of hypertension after transplantation 16 and it is considered both as a consequence of reduced renal function and a risk for graft failure. Although several studies implicated acute rejection as a major risk factor for chronic allograft failure, 10,17,18 in contrast to others, 19,20 notably, we found a long-term allograft survival despite early acute rejection. The timing of the occurrence of acute rejection has been described to affect graft survival. 21 In our series, any acute rejection occurring later than one year post-transplantation significantly impacted graft survival. One could speculate that acute rejection episodes occurring late post-transplantation are due to pathophysiological processes different from the ones involved in early rejections; thus, the efficacy of the traditional immunosuppressive regimens would be compromised. Alternatively, those rejections could just be a marker for otherwise undetectable non-compliance with immunosuppressive medications. The biopsy features in our study patients revealed that the rate of moderate and severe acute rejection was not high in either the shortor long-term surviving grafts. The correlation between the elevated serum creatinine levels at 12 months and graft survival has been documented in multi-center studies. 22 This correlation was also present in our study population and can be explained by the degree of graft dysfunction due to nephron loss from nonimmunological causes or the undetected lowgrade chronic immunologic injury. Regardless of the etiology, the variance in creatinine levels observed during the first year, as described in our population, could function as a sensitive early marker of such processes. Although diabetes mellitus developed in six (10.7%) of our patients during the post-transplantation course, it had no significant impact on graft survival. Other medical complications such as coronary heart disease (9.4%) and malignancy (3.2%) were relatively uncommon, which may be attributed to the policy of selection of young patients in our transplantation program. Post-transplant infection was not uncommon among our long-term allograft survivors (35.5%); urinary tract and upper respiratory tract infection were the most common without significant morbidity. Our patients on CsA-based immunosuppression clearly did not show any significant benefit on long-term quality of graft function than the patients on AZA and steroids. Moreover, we found that post-transplant hypertension and cardiovascular morbidity were more statistically significantly prevalent in the CsA-treated patients, and the mean serum creatinine early in the first year post-transplant was also significantly higher in this group; however, this was not the case at the last follow-up visit. Our data are not in agreement with many other studies, 23,24 and early replacement of CsA by another immunosuppressive agent to prevent the long-term toxicity should be considered. In conclusion, renal transplantation even in its earliest years and despite the numerous complications has provided ten or more years of nearnormal life to patients with ESRD, who otherwise would remain dialysis dependent. Interestingly, absence of post-transplantation hypertension and severe and late acute rejections together with good graft function at one year could predict good long-term graft outcome. References 1. Fletcher SM, Novick AC, Braun WE, Popowaniak KL, Steinmuller D. Functional capacity and reha-
7 824 Alarrayed S, El-Agroudy A, Al-Arrayed A, et al bilitation of recipients with a functioning renal allograft for ten year or more. Transplantation 1983;35: Terasaki PI, McClelland ID, Yuge J, et al. Advances in kidney transplantation , in Cecka JM, Terasaki PI (eds.): Clinical transplants. 1995, Los Angeles, CA, UCLA Tissue Typing Laboratory, 1996; Tanaka T, Takahara S, Hatori M, et al. The differences between late graft loss group and longterm graft survival group in renal transplantation. Clin Transplant 2000;15(Suppl 5): El-Agroudy AE, Bakr MA, Hassan NA, et al. Characteristics of long-term live-donor renal allograft survivors. Am J Nephrol 2003;23: Meier-Kriesche H, Schold JD, Kaplan B. Longterm renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004;4: de Mattos AM, Bennett WM, Barry JM, Norman DJ. HLA-identical sibling renal transplantation: A 21-yr single-center experience. Clin Transplant 1999;13: Tojimbara T, Fuchinouea S, Iwadoha K, et al. Improved outcomes of renal transplantation from cardiac death donors: A 30-year single center experience. Am J Transplant 2007;7: Soleza K, Colvinb RB, Racusenc LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008;8: Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ Stablein D. Improved graft survival and renal transplantation in the United States, 1988 to N Engl J Med 2000;342 (9): Kyllonen L, Koshimies S, Salmela K. Renal transplant recipients with graft survival longer than 20 years: Report on 107 cases. Transplant Proc 2001;33(4): Gueco IP, Evans BD, Calne RY. Prolonged survival after renal transplantation. A study of 54 patients who lived ten or more years after operation with functioning allografts. Transplant Proc 1985;17(1): Mahony JF. Long-term results and complications of transplantation: The kidney. Transplant Proc 1989;21(1): Silkensen JR. Long-term complications in renal transplantation. J Am Soc Nephrol 2000;11(3): Golbabaic M, Kayedi M, Nojafi I, et al. Chronic renal allograft dysfunction: Immunologic and nonimmunologic risk factors. Transplant Proc 2001;33(5): Opelz G, Wujciak T, Ritz E. the Collaborative Transplant Study. Association of chronic kidney graft failure with recipient blood pressure. Kidney Int 1998;53: Manage KC, Cizman B, Jaffe M, Feldman HI. Arterial hypertension and renal allograft survival. JAMA 2000;283(5): Bruan WE, Popowniak KL, Nakamoto S, Gifford RW, Straffon RA. The fate of renal allografts functioning for a minimum of 20 yr- indefinite success or beginning of the end? A proposed classification of long-term allograft survivals. Transplantation 1995;60: Prommool S, Jhangri GS, Cockfield SM, Halloran PF. Time dependency of factors affecting renal allograft survival. J Am Soc Nephrol 2000;11 (3): Ashraf S, Parrott N, Dyer P. Clinical response and temporal patterns of acute cellular rejection: relationship to chronic transplant nephropathy. Transplant Int 1998;11(1): Varghese Z. Immunologic and nonimmunologic correlates of chronic renal allograft dysfunction. Transplant Proc 1999;31(8): Joseph JT, Kingsmore DB, Junor BJ, et al. The impact of late acute rejection after cadaveric kidney transplantation. Clin Transplant 2001; 15: Troppmann C, Gillingham KJ, Benedetti E, et al. Delayed graft function, acute rejection, and outcome after cadaver renal transplantation. Transplantation 1995;59(7): Opelz G. HLA compatibility and kidney grafts from unrelated live donors, Collaborative Transplant Study. Transplant Proc 1998;30(3): Halloran PF. Immunosuppression in the postadaptation period. Transplantation 2000;70:3-5.
Clinical Study Over Ten-Year Kidney Graft Survival Determinants
International Nephrology Volume 2012, Article ID 302974, 5 pages doi:10.1155/2012/302974 Clinical Study Over Ten-Year Kidney Graft Survival Determinants Anabela Malho Guedes, 1, 2 Jorge Malheiro, 1 Isabel
More informationBK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy
BK virus infection in renal transplant recipients: single centre experience Dr Wong Lok Yan Ivy Background BK virus nephropathy (BKVN) has emerged as an important cause of renal graft dysfunction in recent
More informationSELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80%
SELECTED ABSTRACTS The following are summaries of selected posters presented at the American Transplant Congress on May 5 9, 2007, in San Humar A, Gillingham KJ, Payne WD, et al. Review of >1000 kidney
More informationLong-term prognosis of BK virus-associated nephropathy in kidney transplant recipients
Original Article Kidney Res Clin Pract 37:167-173, 2018(2) pissn: 2211-9132 eissn: 2211-9140 https://doi.org/10.23876/j.krcp.2018.37.2.167 KIDNEY RESEARCH AND CLINICAL PRACTICE Long-term prognosis of BK
More informationReduced graft function (with or without dialysis) vs immediate graft function a comparison of long-term renal allograft survival
Nephrol Dial Transplant (2006) 21: 2270 2274 doi:10.1093/ndt/gfl103 Advance Access publication 22 May 2006 Original Article Reduced graft function (with or without dialysis) vs immediate graft function
More informationAcute rejection and late renal transplant failure: Risk factors and prognosis
Nephrol Dial Transplant (2004) 19 [Suppl 3]: iii38 iii42 DOI: 10.1093/ndt/gfh1013 Acute rejection and late renal transplant failure: Risk factors and prognosis Luis M. Pallardo Mateu 1, Asuncio n Sancho
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright, 2, by the Massachusetts Medical Society VOLUME 342 M ARCH 2, 2 NUMBER 9 IMPROVED GRAFT SURVIVAL AFTER RENAL TRANSPLANTATION IN THE UNITED STATES, 1988 TO
More informationEfficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function
ArtIcle Efficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function Guodong Chen, 1 Jingli Gu, 2 Jiang Qiu, 1 Changxi
More informationManagement of Rejection
Management of Rejection I have no disclosures Disclosures (relevant or otherwise) Deborah B Adey, MD Professor of Medicine University of California, San Francisco Kidney and Pancreas Transplant Center
More informationJ Am Soc Nephrol 14: , 2003
J Am Soc Nephrol 14: 208 213, 2003 Kidney Allograft and Patient Survival in Type I Diabetic Recipients of Cadaveric Kidney Alone Versus Simultaneous Pancreas/Kidney Transplants: A Multivariate Analysis
More informationIntruduction PSI MODE OF ACTION AND PHARMACOKINETICS
Multidisciplinary Insights on Clinical Guidance for the Use of Proliferation Signal Inhibitors in Heart Transplantation Andreas Zuckermann, MD et al. Department of Cardio-Thoracic Surgery, Medical University
More informationSteroid Minimization: Great Idea or Silly Move?
Steroid Minimization: Great Idea or Silly Move? Disclosures I have financial relationship(s) within the last 12 months relevant to my presentation with: Astellas Grants ** Bristol Myers Squibb Grants,
More informationConsidering the early proactive switch from a CNI to an mtor-inhibitor (Case: Male, age 34) Josep M. Campistol
Considering the early proactive switch from a CNI to an mtor-inhibitor (Case: Male, age 34) Josep M. Campistol Patient details Name DOB ESRD Other history Mr. B.I.B. 12 January 1975 (34yo) Membranous GN
More informationEchocardiography analysis in renal transplant recipients
Original Research Article Echocardiography analysis in renal transplant recipients S.A.K. Noor Mohamed 1*, Edwin Fernando 2, 1 Assistant Professor, 2 Professor Department of Nephrology, Govt. Stanley Medical
More informationNephrology Dialysis Transplantation
Nephrol Dial Transplant (1999) 14: 394 399 Original Article Nephrology Dialysis Transplantation Reduced kidney transplant rejection rate and pharmacoeconomic advantage of mycophenolate mofetil Rudolf P.
More informationJames E. Cooper, M.D. Assistant Professor, University of Colorado at Denver Division of Renal Disease and Hypertension, Kidney and PancreasTransplant
James E. Cooper, M.D. Assistant Professor, University of Colorado at Denver Division of Renal Disease and Hypertension, Kidney and PancreasTransplant Program Has no real or apparent conflicts of interest
More informationLiterature Review Transplantation
Literature Review 2010- Transplantation Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas Transplant Programs University of
More informationIncidence of Rejection in Renal Transplant Surgery in the LVHN Population Leading to Graft Failure: 6 Year Review
Incidence of Rejection in Renal Transplant Surgery in the LVHN Population Leading to Graft Failure: 6 Year Review Jessica Ludolph 1 Lynsey Biondi, MD 1,2 and Michael Moritz, MD 1,2 1 Department of Surgery,
More informationRENAL TRANSPLANTATION HAS
ORIGINAL CONTRIBUTION Arterial Hypertension and Renal Allograft Survival Kevin C. Mange, MD Borut Cizman, MD Marshall Joffe, MD, PhD Harold I. Feldman, MD, MSCE Context Several observational studies have
More informationLe migliori strategie immunosoppressive per il paziente con re-trapianto Prof. Maurizio Salvadori FIRENZE
Le migliori strategie immunosoppressive per il paziente con re-trapianto Prof. Maurizio Salvadori FIRENZE Best Therapy for Kidney Re- Transplantation? PREVENTION!!!! Registries CTS OPTN UNOS USRDS SRTR
More informationHLA and Non-HLA Antibodies in Transplantation and their Management
HLA and Non-HLA Antibodies in Transplantation and their Management Luca Dello Strologo October 29 th, 2016 Hystory I 1960 donor specific antibodies (DSA): first suggestion for a possible role in deteriorating
More informationTransplantation in Australia and New Zealand
Transplantation in Australia and New Zealand Matthew D. Jose MBBS (Adel), FRACP, FASN, PhD (Monash), AFRACMA Professor of Medicine, UTAS Renal Physician, Royal Hobart Hospital Overview CKD in Australia
More informationSirolimus versus Calcineurin Inhibitor-based Immunosuppressive Therapy in Kidney Transplantation A 4-year Follow-up
Transplantation Sirolimus versus Calcineurin Inhibitor-based Immunosuppressive Therapy in Kidney Transplantation A 4-year Follow-up Mohsen Nafar, 1 Behrang Alipour, 2 Pedram Ahmadpoor, 1 Fatemeh Pour-Reza-Gholi,
More informationTolerance Induction in Transplantation
Tolerance Induction in Transplantation Reza F. Saidi, MD, FACS, FICS Assistant Professor of Surgery Division of Organ Transplantation Department of Surgery University of Massachusetts Medical School Percent
More informationCHAPTER 14. Renal Transplantation
15th Report of the Malaysian RENAL TRANSPLANTATION CHAPTER 14 Renal Transplantation Editor: Dr. Goh Bak Leong Expert Panel: : Dato Dr. Dato Zaki Dr. Morad Zaik Morad Mohd (Chair) Zaher (Chair) Dr. Goh
More informationCHAPTER 5 RENAL TRANSPLANTATION. Editor: Dr Goh Bak Leong
CHAPTER 5 RENAL TRANSPLANTATION Editor: Dr Goh Bak Leong Expert Panel: Dr Goh Bak Leong (Chair) Dato Dr (Mr) Rohan Malek Dr Wong Hin Seng Dr Fan Kin Sing Dr Rosnawati Yahya Dr S Prasad Menon Dr Tan Si
More informationNAPRTCS Annual Transplant Report
North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 2010 Annual Transplant Report This is a privileged communication not for publication. TABLE OF CONTENTS PAGE I INTRODUCTION 1 II
More informationTransplantation in highly sensitised patients treated with intravenous immunoglobulin and Rituximab
ORIGINAL ARTICLE Advance Access publication 1 February 2010 Transplantation in highly sensitised patients treated with intravenous immunoglobulin and Rituximab Ana Carina Ferreira 1, Sandra Brum 1, Vasco
More informationChronic Kidney Disease (CKD) Stages. CHRONIC KIDNEY DISEASE Treatment Options. Incident counts & adjusted rates, by primary diagnosis Figure 2.
Chronic Kidney Disease (CKD) Stages Stage 1 GFR > 90 (evidence of renal disease) Stage 2 GFR 60-89 Stage 3 GFR 30-59 Stage 4 GFR 15-29 Stage 5 GFR
More informationOur Experiences in Kidney Transplantation and Monitoring of Kidney Graft Outcomes
& Our Experiences in Kidney Transplantation and Monitoring of Kidney Graft Outcomes Rašić Senija¹*, Džemidžić Jasminka¹, Aganović Kenana¹, Aganović Damir², Prcić Alden² 1. Institute of Nephrology, Clinical
More informationRecurrent Idiopathic Membranous Glomerulonephritis After Kidney Transplantation and Successful Treatment With Rituximab
TRANSPLANTATION Recurrent Idiopathic Membranous Glomerulonephritis After Kidney Transplantation and Successful Treatment With Rituximab Khadijeh Makhdoomi, 1,2 Saeed Abkhiz, 1,2 Farahnaz Noroozinia, 1,3
More informationKidney Allograft Fibrosis and Atrophy Early After Living Donor Transplantation
American Journal of Transplantation 2005; 5: 1130 1136 Blackwell Munksgaard Copyright C Blackwell Munksgaard 2005 doi: 10.1111/j.1600-6143.2005.00811.x Kidney Allograft Fibrosis and Atrophy Early After
More informationProgress in Pediatric Kidney Transplantation
Send Orders for Reprints to reprints@benthamscience.net The Open Urology & Nephrology Journal, 214, 7, (Suppl 2: M2) 115-122 115 Progress in Pediatric Kidney Transplantation Jodi M. Smith *,1 and Vikas
More informationNAPRTCS Annual Transplant Report
North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 2014 Annual Transplant Report This is a privileged communication not for publication. TABLE OF CONTENTS PAGE II TRANSPLANTATION Section
More informationEmerging Drug List EVEROLIMUS
Generic (Trade Name): Manufacturer: Everolimus (Certican ) Novartis Pharmaceuticals NO. 57 MAY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence: For use with cyclosporine
More informationFor more information about how to cite these materials visit
Author(s): Silas P. Norman, M.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution Noncommercial Share Alike 3.0 License: http://creativecommons.org/licenses/by-nc-sa/3.0/
More informationPredictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
Pediatr Transplantation 2013: 17: 436 440 2013 John Wiley & Sons A/S. Pediatric Transplantation DOI: 10.1111/petr.12095 Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
More informationRejection or Not? Interhospital Renal Meeting 10 Oct Desmond Yap & Sydney Tang Queen Mary Hospital
Rejection or Not? Interhospital Renal Meeting 10 Oct 2007 Desmond Yap & Sydney Tang Queen Mary Hospital Case Presentation F/61 End stage renal failure due to unknown cause Received HD in private hospital
More informationPatient And Allograft Survival After Transplantation
Patient And Allograft Survival After Transplantation With A Living Donor Kidney: 14 Years Experience*. Saidi Hassan M.Med (Surg), Departments of Human Anatomy & Surgery, University of Nairobi. Email:hsaid2ke@yahoo.com
More information2017 CST-Astellas Canadian Transplant Fellows Symposium. Management of Renal Dysfunction in Extra Renal Transplants
2017 CST-Astellas Canadian Transplant Fellows Symposium Management of Renal Dysfunction in Extra Renal Transplants Jeffrey Schiff, MD Dr. Jeffrey Schiff is an Assistant Professor of Medicine at the University
More informationShould Pediatric Patients Wait for HLA-DR-Matched Renal Transplants?
American Journal of Transplantation 2008; 8: 2056 2061 Wiley Periodicals Inc. C 2008 The Authors Journal compilation C 2008 The American Society of Transplantation and the American Society of Transplant
More informationIncreased Early Rejection Rate after Conversion from Tacrolimus in Kidney and Pancreas Transplantation
Increased Early Rejection Rate after Conversion from Tacrolimus in Kidney and Pancreas Transplantation Gary W Barone 1, Beverley L Ketel 1, Sameh R Abul-Ezz 2, Meredith L Lightfoot 1 1 Department of Surgery
More informationDownloaded from ismj.bpums.ac.ir at 20: on Friday March 22nd 2019
- ( ) - -. :. ( ) :.. :... :. : // : -// : Email :Kazem_an@modares.ac.ir /..().(). ) (HLA.(). ( ) ( ). ) () ( ) ( () () () ( ). ().().().().().() (). / / / /..().. / / : (LDL). SPSS) SPSS STATA. (Inc,
More informationTen-year survival of second kidney transplants: Impact of immunologic factors and renal function at 12 months
Kidney International, Vol. 64 (2003), pp. 674 680 Ten-year survival of second kidney transplants: Impact of immunologic factors and renal function at 12 months STÉPHANIE COUPEL, MAGALI GIRAL-CLASSE, GEORGES
More informationABO-incompatible kidney transplantation in elderly patients over 60 years of age
Int Urol Nephrol (2012) 44:1563 1570 DOI 10.1007/s11255-012-0231-z NEPHROLOGY - ORIGINAL PAPER ABO-incompatible kidney transplantation in elderly patients over 60 years of age Junji Uchida Tomoaki Iwai
More informationAmerican Journal of Transplantation 2009; 9 (Suppl 3): S1 S157 Wiley Periodicals Inc.
American Journal of Transplantation 2009; 9 (Suppl 3): S1 S157 Wiley Periodicals Inc. 2009 The Authors Journal compilation 2009 The American Society of Transplantation and the American Society of Transplant
More informationSerum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant
SDC, Patients and Methods Complement-dependent lymphocytotoxic crossmatch test () Serum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant donor-specific CXM was
More informationCase Presentation Turki Al-Hussain, MD
Case Presentation Turki Al-Hussain, MD Director, Renal Pathology Chapter Saudi Society of Nephrology & Transplantation Consultant Nephropathologist & Urological Pathologist Department of Pathology & Laboratory
More informationCHAPTER 5 RENAL TRANSPLANTATION. Editor: Dr Rosnawati Yahya
CHAPTER 5 Editor: Dr Rosnawati Yahya Expert Panels: Dr Rosnawati Yahya Dr Ng Kok Peng Dr Suryati Binti Yakaob Dr Mohd Zaimi Abd Wahab Dr Yee Seow Ying Dr Wong Hin Seng Contents 5. Stock and Flow of Renal
More informationRecognition and Treatment of Chronic Allograft Dysfunction
Recognition and Treatment of Chronic Allograft Dysfunction Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas Transplant Programs
More informationCalcineurin inhibitors in HLA-identical living related donor kidney transplantation
Nephrol Dial Transplant (2014) 29: 209 218 doi: 10.1093/ndt/gft447 Calcineurin inhibitors in HLA-identical living related donor kidney transplantation ABSTRACT Priya S. Verghese 1, Ty B. Dunn 2, Srinath
More informationCHAPTER 5 RENAL TRANSPLANTATION. Editor: Dr Goh Bak Leong
CHAPTER 5 RENAL TRANSPLANTATION Editor: Dr Goh Bak Leong Expert Panel: Dr Goh Bak Leong (Chair) Dato Dr Zaki Morad Mohd Zaher Dato Dr (Mr) Rohan Malek Dr Fan Kin Sing Dr Lily Mushahar Dr Lim Soo Kun Dr
More informationHigher tacrolimus trough levels on days 2 5 post-renal transplant are associated with reduced rates of acute rejection
Clin Transplant 2009: 23: 462 468 DOI: 10.1111/j.1399-0012.2009.01021.x ª 2009 John Wiley & Sons A/S. Higher tacrolimus trough levels on days 2 5 post-renal transplant are associated with reduced rates
More informationEuropean Risk Management Plan. Measures impairment. Retreatment after Discontinuation
European Risk Management Plan Table 6.1.4-1: Safety Concern 55024.1 Summary of Risk Minimization Measures Routine Risk Minimization Measures Additional Risk Minimization Measures impairment. Retreatment
More informationEvaluation of 84 elderly donors in renal transplantation
Clin Transplant 2004: 18: 440 445 DOI: 10.1111/j.1399-0012.2004.00186.x Copyright ª Blackwell Munksgaard 2004 Evaluation of 84 elderly donors in renal transplantation Rigotti P, Baldan N, Valente M, Scappin
More informationPancreas After Islet Transplantation: A First Report of the International Pancreas Transplant Registry
American Journal of Transplantation 2016; 16: 688 693 Wiley Periodicals Inc. Brief Communication Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons doi:
More informationChapter 6: Transplantation
Chapter 6: Transplantation Introduction During calendar year 2012, 17,305 kidney transplants, including kidney-alone and kidney plus at least one additional organ, were performed in the United States.
More informationSINCE the introduction of Imuran and
Cadaveric Renal Transplantation With Cyclosporin-A and Steroids T. R. Hakala, T. E. Starzl, J. T. Rosenthal, B. Shaw, and S. watsuki SNCE the introduction of muran and prednisone in 1961, and despite the
More informationShould red cells be matched for transfusions to patients listed for renal transplantation?
Should red cells be matched for transfusions to patients listed for renal transplantation? Dr M.Willicombe Imperial College Renal and Transplant Centre, Hammersmith Hospital Should red cells be matched
More informationWhy Do We Need New Immunosuppressive Agents
Why Do We Need New Immunosuppressive Agents 1 Reducing acute rejection rates has not transplanted into better long-term graft survival Incidence of early acute rejection episodes by era Relative risk for
More informationHLA-Matched Kidney Transplantation in the Era of Modern Immunosuppressive Therapy
HLA-Matched Kidney Transplantation in the Era of Modern Immunosuppressive Therapy Arun Amatya, MD; Sandy Florman, MD; Anil Paramesh, MD; Anup Amatya, PhD Jennifer McGee, MD; Mary Killackey, MD; Quing Ren,
More informationReview of Rituximab and renal transplantation. Dr.E Nemati. Professor of Nephrology
Review of Rituximab and renal transplantation Dr.E Nemati Professor of Nephrology Introductio n Rituximab is a chimeric anti-cd20 monoclonal antibody. The CD20 antigen is a transmembrane nonglycosylated
More informationLong-term outcome of third kidney transplants
Nephrol Dial Transplant (27) 22: 2693 27 doi:1.193/ndt/gfm226 Advance Access publication 23 April 27 Original Article Long-term outcome of third kidney transplants Alexandre Loupy 1, Dany Anglicheau 1,
More informationCOMPARISON OF THE SURVIVAL OF SHIPPED AND LOCALLY TRANSPLANTED CADAVERIC RENAL ALLOGRAFTS
COMPARISON OF THE SURVIVAL OF SHIPPED AND LOCALLY TRANSPLANTED CADAVERIC RENAL ALLOGRAFTS A COMPARISON OF THE SURVIVAL OF SHIPPED AND LOCALLY TRANSPLANTED CADAVERIC RENAL ALLOGRAFTS KEVIN C. MANGE, M.D.,
More informationTransplant Success in Sensitized Patients Receiving a Standardized Desensitization Therapy: 3 Year Outcomes
Transplant Success in Sensitized Patients Receiving a Standardized Desensitization Therapy: 3 Year Outcomes INTRODUCTION In patients awaiting a transplant, having antibodies reactive to HLA antigens present
More informationCHAPTER 3 HEART AND LUNG TRANSPLANTATION. Editors: Mr. Mohamed Ezani Hj Md. Taib Dato Dr. David Chew Soon Ping
CHAPTER 3 Editors: Mr. Mohamed Ezani Hj Md. Taib Dato Dr. David Chew Soon Ping Expert Panel: Tan Sri Dato Dr. Yahya Awang (Chair) Mr. Mohamed Ezani Hj Md. Taib (Co-chair) Datin Dr. Aziah Ahmad Mahayiddin
More informationOUT OF DATE. Choice of calcineurin inhibitors in adult renal transplantation: Effects on transplant outcomes
nep_734.fm Page 88 Friday, January 26, 2007 6:47 PM Blackwell Publishing AsiaMelbourne, AustraliaNEPNephrology1320-5358 2006 The Author; Journal compilation 2006 Asian Pacific Society of Nephrology? 200712S18897MiscellaneousCalcineurin
More informationGUIDELINES ON RENAL TRANSPLANTATION
46 GUIDELINES ON RENAL TRANSPLANTATION T. Kälbe (chairman), M. Lucan, G. Nicita, R. Sells, F.J. Burgos Revilla, M. Wiesel Introduction The number of patients registered as starting end-stage renal disease
More informationLiterature Review: Transplantation July 2010-June 2011
Literature Review: Transplantation July 2010-June 2011 James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver Kidney Transplant Top 10 List: July Kidney
More informationEarly assessment of renal resistance index after kidney transplant can help predict long-term renal function
Nephrol Dial Transplant (2006) 21: 2916 2920 doi:10.1093/ndt/gfl203 Advance Access publication 5 August 2006 Original Article Early assessment of renal resistance index after kidney transplant can help
More informationControversies in Renal Transplantation. The Controversial Questions. Patrick M. Klem, PharmD, BCPS University of Colorado Hospital
Controversies in Renal Transplantation Patrick M. Klem, PharmD, BCPS University of Colorado Hospital The Controversial Questions Are newer immunosuppressants improving patient outcomes? Are corticosteroids
More informationWhat is the Best Induction Immunosuppression Regimen in Kidney Transplantation? Richard Borrows: Queen Elizabeth Hospital Birmingham
What is the Best Induction Immunosuppression Regimen in Kidney Transplantation? Richard Borrows: Queen Elizabeth Hospital Birmingham SYMPHONY Study Ekberg et al. NEJM 2008 Excluded: DCD kidneys; CIT>30hours;
More informationClinical Outcomes of Renal Transplantation in Hepatitis C Virus Positive Recipients
Original Research Article Clinical Outcomes of Renal Transplantation in Hepatitis C Virus Positive Recipients Surendran Sujit 1*, N. Gopalakrishnan 2 1 Assistant Professor, 2 Professor and Head Department
More informationDiabetes Mellitus GUIDELINES UNGRADED SUGGESTIONS FOR CLINICAL CARE IMPLEMENTATION AND AUDIT BACKGROUND
Diabetes Mellitus Date written: November 2011 Author: Scott Campbell GUIDELINES a. We recommend that diabetes should not on its own preclude a patient from being considered for kidney transplantation (1D).
More informationCHAPTER 5 RENAL TRANSPLANTATION
CHAPTER 5 RENAL TRANSPLANTATION Editor: Dr. Goh Bak Leong Expert Panel: Dato Dr. Zaki Morad b Mohd Zaher (Chair) Dr. Goh Bak Leong (Co-Chair) Dr. Fan Kin Sing Dr. Lily Mushahar Mr. Rohan Malek Dr. S. Prasad
More informationThe New Kidney Allocation System: What You Need to Know. Anup Patel, MD Clinical Director Renal and Pancreas Transplant Division Barnabas Health
The New Kidney Allocation System: What You Need to Know Anup Patel, MD Clinical Director Renal and Pancreas Transplant Division Barnabas Health ~6% of patients die each year on the deceased donor waiting
More informationRISK FACTORS FOR ACUTE TUBULAR NECROSIS IN 774 CADAVER RENAL TRANSPLANTATIONS
Clinical Urology Brazilian Journal of Urology Official Journal of the Brazilian Society of Urology Vol. 28 (2): 93-101, March - April, 2002 RISK FACTORS FOR ACUTE TUBULAR NECROSIS IN 774 CADAVER RENAL
More informationDonor-derived Cell-free DNA Improves DSA-informed Diagnosis of ABMR in Kidney Transplant Patients
Donor-derived Cell-free DNA Improves DSA-informed Diagnosis of ABMR in Kidney Transplant Patients Stanley C. Jordan, MD Director, Division of Nephrology Medical Director, Kidney Transplant Program Medical
More informationEarly Postoperative Urine Flow Predicts Delayed Graft Function Irrespective of Diuretic Use
Early Postoperative Urine Flow Predicts Delayed Graft Function Irrespective of Diuretic Use Sunil Bhandari, PhD, FRCP * David Eisinger, MD, FRACS Josette Eris, PhD, FRACP * *Department of Transplant Medicine,
More informationKidney Transplant in the Elderly. Robert Santella, M.D., F.A.C.P.
Kidney Transplant in the Elderly! Robert Santella, M.D., F.A.C.P. Incident Rate of ESRD by Age Age 75+ 65-74 From US Renal Data System, 2012 Should there be an age limit? Various guidelines: Canadian,
More informationDefinitions. You & Your New Transplant ` 38
Definitions Acute Short, relatively severe Analgesic Pain medicine Anemia A low number of red blood cells Anesthetic Medication that dulls sensation in order to reduce pain Acute Tubular Necrosis (ATN)
More informationRenal Transplant. Tony Chacon. Program Head BCIT Nephrology Nursing Program.
Renal Transplant Tony Chacon Program Head BCIT Nephrology Nursing Program Email: tony_chacon@bcit.ca Summary of CNA Renal Transplant Competencies Potential contraindications to renal transplant. Assessment/selection
More informationEffect of long-term steroid withdrawal in renal transplant recipients: a retrospective cohort study
NDT Plus (2010) 3 [Suppl 2]: ii32 ii36 doi: 10.1093/ndtplus/sfq064 Effect of long-term steroid withdrawal in renal transplant recipients: a retrospective cohort study Miguel Gonzalez-Molina 1, Miguel Angel
More informationFive years of living donor kidney transplantation at University clinical center Tuzla, Bosnia and Herzegovina, from 1999 through 2004
Clinical Science Five years of living donor kidney transplantation at University clinical center Tuzla, Bosnia and Herzegovina, from 1999 through 2004 Senaid Trnačević 1, Goran Imamović 2, Mustafa Bazardžanović
More informationOutcomes of living donor kidney transplantation in diabetic patients: age and sex matched comparison with non-diabetic patients
ORIGINAL ARTICLE Korean J Intern Med 2018;33:356-366 Outcomes of living donor kidney transplantation in diabetic patients: age and sex matched comparison with non-diabetic patients Chung Hee Baek 1, Hyosang
More informationPathological back-ground of renal transplant pathology and important mile-stones of the Banff classification
Banff 1 Banff Pathological back-ground of renal transplant pathology and important mile-stones of the Banff classification Department of Nephrology, Japanese Red Cross Nagoya Daini Hospital Morozumi Kunio,
More informationAlemtuzumab Induction in Non-Hepatitis C Positive Liver Transplant Recipients
LIVER TRANSPLANTATION 17:32-37, 2011 ORIGINAL ARTICLE Alemtuzumab Induction in Non-Hepatitis C Positive Liver Transplant Recipients Josh Levitsky, 1,2 Kavitha Thudi, 1 Michael G. Ison, 1,3 Edward Wang,
More informationOrgan rejection is one of the serious
Original Article Outcomes of Late Corticosteroid Withdrawal after Renal Transplantation in Patients Exposed to Tacrolimus and/or Mycophenolate Mofetil: Meta-Analysis of Randomized Controlled Trials A.
More informationRisk factors associated with the deterioration of renal function after kidney transplantation
Kidney International, Vol. 68, Supplement 99 (2005), pp. S113 S117 Risk factors associated with the deterioration of renal function after kidney transplantation DANIEL SERÓN, XAVIER FULLADOSA, and FRANCESC
More informationLiver Transplantation for Alcoholic Liver Disease in the United States: 1988 to 1995
Liver Transplantation for Alcoholic Liver Disease in the United States: 1988 to 1995 Steven H. Belle, Kimberly C. Beringer, and Katherine M. Detre T he Scientific Liver Transplant Registry (LTR) was established
More informationAnalysis of the Results of ABO-Incompatible Kidney Transplantation: In Comparison with ABO-Compatible Kidney Transplantation
www.kjurology.org DOI:10.4111/kju.2010.51.12.863 Transplantation Analysis of the Results of ABO-Incompatible Kidney Transplantation: In Comparison with ABO-Compatible Kidney Transplantation Byung Joo Jeon,
More informationCURRICULUM VITAE July 5, Name Chang-Kwon Oh. Date of Birth August 15, 1961
CURRICULUM VITAE July 5, 2014 Name Chang-Kwon Oh Date of Birth August 15, 1961 Present Academic & Hospital Appointment Professor, Department of Surgery Ajou University, School of Medicine Chief, Department
More informationMycophenolate mofetil in low-risk renal transplantation in patients receiving no cyclosporine: a single-centre experience
840 O.A. Raheem et al. Nephrol Dial Transplant (2012) 27: 840 844 doi: 10.1093/ndt/gfr263 Advance Access publication 28 May 2011 Mycophenolate mofetil in low-risk renal transplantation in patients receiving
More informationEffects of pretransplant plasmapheresis and rituximab on recurrence of focal segmental glomerulosclerosis in adult renal transplant recipients
ORIGINAL ARTICLE Korean J Intern Med 2014;29:482-488 Effects of pretransplant plasmapheresis and rituximab on recurrence of focal segmental glomerulosclerosis in adult renal transplant recipients Hoon
More informationCigarette Smoking in Renal Transplant Recipients
Cigarette Smoking in Renal Transplant Recipients J Am Soc Nephrol 11: 753 759, 2000 BERTRAM L. KASISKE and DAGMAR KLINGER Department of Medicine, Division of Nephrology, Hennepin County Medical Center,
More informationCHAPTER 5 RENAL TRANSPLANTATION. Editor: Rosnawati Yahya. Expert Panels: Hooi Lai Seong Ng Kok Peng Suryati Binti Yakaob Wong Hin Seng.
CHAPTER 5 Editor: Roswati Yahya Expert Panels: Hooi Lai Seong Ng Kok Peng Suryati Binti Yakaob Wong Hin Seng Contents 5. Stock and Flow of Rel Transplantation Stock and Flow Transplant Rates 5.2 Recipients
More informationIV.13 Analysis of patient and graft survival. Guidelines. Commentary on Guidelines IV.13: Analysis of patient and graft survival
60 SECTION IV: Long-term management of the transplant recipient IV.13 Analysis of patient and graft survival Guidelines A. It is important for a transplant unit to follow-up on the results of their transplant
More informationPrevalence and Risk Factors of Recurrent Cytomegalovirus Infection in Kidney Transplant Recipients
TRANSPLANTATION Prevalence and Risk Factors of Recurrent Cytomegalovirus Infection in Kidney Transplant Recipients Mohsen Nafar, 1 Azamolsadat Roshan, 2 Fatemeh Pour-Reza-Gholi, 1 Fariba Samadian, 1 Pedram
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/29755 holds various files of this Leiden University dissertation. Author: Moes, Dirk Jan Alie Roelof Title: Optimizing immunosuppression with mtor inhibitors
More informationPatient Education Transplant Services. Glossary of Terms. For a kidney/pancreas transplant
Patient Education Glossary of Terms For a kidney/pancreas transplant Glossary of Terms Page 18-2 Antibody A protein substance made by the body s immune system in response to a foreign substance. Antibodies
More information